Rain Therapeutics Inc.
NASDAQ:RAIN
Overview | Financials
Company Name | Rain Therapeutics Inc. |
Symbol | RAIN |
Currency | USD |
Price | 1.21 |
Market Cap | 44,014,599 |
Dividend Yield | 0% |
52-week-range | 0.82 - 11.32 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Avanish Vellanki M.B.A. |
Website | https://www.rainthera.com |
An error occurred while fetching data.
About Rain Therapeutics Inc.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD